The Early-Onset Alzheimer’s Disease Whole-Genome Sequencing Project: Study design and methodology

Author(s): Ray, NR; Ayodele, T; Jean-Francois, M; Baez, P; Fernandez, V; Bradley, J; Crane, PK; Dalgard, CL; Kuzma, A; Nicaretta, H; Sims, R; Williams, J; Cuccaro, ML; Pericak-Vance, MA; Mayeux, R; Wang, L; Schellenberg, GD; Cruchaga, C; Beecham, GW; Reitz, C;
Year: 2023;  
Journal: Alzheimer's & Dementia: The Journal of the Alzheimer's Association;  
Volume: 19;  
Issue: 9;  
Abstract:

INTRODUCTION: Sequencing efforts to identify genetic variants and pathways underlying Alzheimer’s disease (AD) have largely focused on late-onset AD although early-onset AD (EOAD), accounting for ∼10% of cases, is largely unexplained by known mutations, resulting in a lack of understanding of its molecular etiology.
METHODS: Whole-genome sequencing and harmonization of clinical, neuropathological, and biomarker data of over 5000 EOAD cases of diverse ancestries.
RESULTS: A publicly available genomics resource for EOAD with extensive harmonized phenotypes. Primary analysis will (1) identify novel EOAD risk loci and druggable targets; (2) assess local-ancestry effects; (3) create EOAD prediction models; and (4) assess genetic overlap with cardiovascular and other traits.
DISCUSSION: This novel resource complements over 50,000 control and late-onset AD samples generated through the Alzheimer’s Disease Sequencing Project (ADSP). The harmonized EOAD/ADSP joint call will be available through upcoming ADSP data releases and will allow for additional analyses across the full onset range.
HIGHLIGHTS: Sequencing efforts to identify genetic variants and pathways underlying Alzheimer’s disease (AD) have largely focused on late-onset AD although early-onset AD (EOAD), accounting for ∼10% of cases, is largely unexplained by known mutations. This results in a significant lack of understanding of the molecular etiology of this devastating form of the disease. The Early-Onset Alzheimer’s Disease Whole-genome Sequencing Project is a collaborative initiative to generate a large-scale genomics resource for early-onset Alzheimer’s disease with extensive harmonized phenotype data. Primary analyses are designed to (1) identify novel EOAD risk and protective loci and druggable targets; (2) assess local-ancestry effects; (3) create EOAD prediction models; and (4) assess genetic overlap with cardiovascular and other traits. The harmonized genomic and phenotypic data from this initiative will be available through NIAGADS.